Analysis of serum lipids, cardiovascular risk, and indication for statin use during nilotinib and imatinib therapy in de novo CML patients - results from real-life prospective study
Leukemia & lymphoma.
2020 Feb ;
61 (2) :
494-496.
[epub] 20191003
Language English Country United States Media print-electronic
Document type Letter, Research Support, Non-U.S. Gov't
Persistent link
https://www.medvik.cz/link/pmid31580157
- MeSH
- Imatinib Mesylate adverse effects MeSH
- Protein Kinase Inhibitors MeSH
- Cardiovascular Diseases * epidemiology etiology MeSH
- Humans MeSH
- Lipids MeSH
- Prospective Studies MeSH
- Antineoplastic Agents * MeSH
- Pyrimidines MeSH
- Heart Disease Risk Factors MeSH
- Risk Factors MeSH
- Hydroxymethylglutaryl-CoA Reductase Inhibitors * adverse effects MeSH
- Check Tag
- Humans MeSH
- Publication type
- Letter MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- Imatinib Mesylate MeSH
- Protein Kinase Inhibitors MeSH
- Lipids MeSH
- nilotinib MeSH Browser
- Antineoplastic Agents * MeSH
- Pyrimidines MeSH
- Hydroxymethylglutaryl-CoA Reductase Inhibitors * MeSH
Department of Hemato Oncology University Hospital Olomouc Olomouc Czech Republic
Department of Hemato Oncology University Hospital Ostrava Ostrava Czech Republic
References provided by Crossref.org
Cancer medicine.
2024 Sep ;
13 (17) :
e70158.
